Effect of lifestyle modification on hepatocellular carcinoma incidence and mortality among patients with chronic hepatitis B

被引:2
|
作者
Park, Yewan [1 ,2 ]
Kang, Danbee [3 ,4 ]
Sinn, Dong Hyun [2 ,5 ]
Kim, Hyunsoo [4 ]
Hong, Yun Soo [6 ,7 ]
Cho, Juhee [3 ,4 ,6 ,7 ]
Gwak, Geum-Youn [5 ]
机构
[1] Kyung Hee Univ Hosp, Dept Internal Med, Seoul 02447, South Korea
[2] Sungkyunkwan Univ, Dept Digital Hlth, SAIHST, Seoul 06355, South Korea
[3] Sungkyunkwan Univ, Dept Clin Res Design & Evaluat, SAIHST, Seoul 06355, South Korea
[4] Sungkyunkwan Univ, Ctr Clin Epidemiol, Samsung Med Ctr, Seoul 06351, South Korea
[5] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul 06351, South Korea
[6] Johns Hopkins Med Inst, Dept Epidemiol & Med, Baltimore, MD 21287 USA
[7] Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21287 USA
关键词
Lifestyle modification; Chronic hepatitis B; Hepatocellular carcinoma; Cancer; Mortality; CHRONIC VIRAL-HEPATITIS; COFFEE CONSUMPTION; CIGARETTE-SMOKING; LIVER-CANCER; ALCOHOL; RISK; INFECTION; DRINKING; TOBACCO;
D O I
10.3748/wjg.v29.i24.3843
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Research exploring the influence of healthier lifestyle modification (LSM) on the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) is limited. AIM To emulate a target trial to determine the effect of LSM on HCC incidence and mortality among patients with CHB by large-scale population-based observational data. METHODS Among the patients with CHB enrolled in the Korean National Health Insurance Service between January 1, 2009, and December 31, 2017, those aged >= 20 years who drank alcohol, smoked cigarettes, and were sedentary were analyzed. Exposure included at least one LSM, including alcohol abstinence, smoking cessation, and regular exercise. The primary outcome was HCC development, and the secondary outcome was liver-related mortality. We used 2:1 propensity score matching to account for covariates. RESULTS With 48766 patients in the LSM group and 103560 in the control group, the adjusted hazard ratio (HR) for incident HCC and liver-related mortality was 0.92 [95% confidence interval (CI): 0.87-0.96] and 0.92 (95%CI: 0.86-0.99) in the LSM group, respectively, compared with the control group. Among the LSM group, the adjusted HR (95%CI) for incident HCC was 0.84 (0.76-0.94), 0.87 (0.81-0.94), and 1.08 (1.00-1.16) for alcohol abstinence, smoking cessation, and regular exercise, respectively. The adjusted HR (95%CI) for liver-related mortality was 0.92 (0.80-1.06), 0.81 (0.72-0.91), and 1.15 (1.04-1.27) for alcohol abstinence, smoking cessation, and regular exercise, respectively. CONCLUSION LSM lowered the risk of HCC and mortality in patients with CHB. Thus, active LSM, particularly alcohol abstinence and smoking cessation, should be encouraged in patients with CHB. (c) The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:3843 / 3854
页数:12
相关论文
共 50 条
  • [41] Liver stiffness and the incidence of hepatocellular carcinoma in patients with chronic hepatitis C
    Nakayama, Yuji
    Takeda, Tadashi
    Yasuda, Takahiro
    Nakaya, Mika
    Nakahara, Kenishi
    Fujii, Hideki
    Kobayashi, Sawako
    Iwai, Shuuji
    Enomoto, Masaru
    Tamori, Akihiro
    Sakaguchi, Hiroki
    Habu, Daiki
    Seki, Shuichi
    Kawada, Nonfumi
    GASTROENTEROLOGY, 2007, 132 (04) : A780 - A780
  • [42] Chronic Hepatitis B and Hepatocellular Carcinoma
    McClune, Amy C.
    Tong, Myron J.
    CLINICS IN LIVER DISEASE, 2010, 14 (03) : 461 - +
  • [43] Rest B Study: Estimating the Incidence of Hepatocellular Carcinoma in a Real World Cohort of Patients with Chronic Hepatitis B
    Kranidioti, Charikleia
    Lonas, Evangelos
    Protopapas, Adonis
    Voulgaris, Theodoros A.
    Tsolias, Chrysostomos
    Deutsch, Melanie
    Triantos, Christos U.
    Goulis, Ioannis
    Papatheodoridis, George V.
    Manolakopoulos, Spilios
    HEPATOLOGY, 2018, 68 : 1234A - 1234A
  • [44] National reimbursement for chronic hepatitis B therapy and incidence of hepatocellular carcinoma in Taiwan
    Wu, Jaw-Ching
    Wu, Chun-Ying
    HEPATOLOGY, 2012, 56 : 388A - 389A
  • [45] A retrospective review of the incidence of hepatocellular carcinoma in patients with chronic hepatitis B attending the regional hepatitis clinic in Northern Ireland
    Carroll, Geraldine
    Cash, Johnny
    Wasson, Gemma
    Braniff, Conor
    McDougall, Neil
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E254 - E254
  • [46] Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy
    Shim, Jae-Jun
    Oh, Chi Hyuck
    Kim, Jung Wook
    Lee, Chang Kyun
    Kim, Byung-Ho
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (09) : 1029 - 1036
  • [47] Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with chronic hepatitis B
    Hosaka, Tetsuya
    Suzuki, Fumitaka
    Kobayashi, Masahiro
    Seko, Yuya
    Kawamura, Yusuke
    Sezaki, Hitomi
    Akuta, Norio
    Suzuki, Yoshiyuki
    Saitoh, Satoshi
    Arase, Yasuji
    Ikeda, Kenji
    Kobayashi, Mariko
    Kumada, Hiromitsu
    HEPATOLOGY, 2012, 56 : 366A - 366A
  • [48] Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
    Lim, Young-Suk
    Chan, Henry L. Y.
    Ahn, Sang Hoon
    Seto, Wai Kay
    Ning, Qin
    Agarwal, Kosh
    Janssen, Harry L. A.
    Pan, Calvin Q.
    Chuang, Wan Long
    Izumi, Namiki
    Fung, Scott
    Shalimar, Maurizia
    Brunetto, Maurizia
    Hui, Aric Josun
    Chang, Ting-Tsung
    Lim, Seng Gee
    Abramov, Frida
    Flaherty, John F.
    Wang, Hongyuan
    Yee, Leland J.
    Kao, Jia-Horng
    Gane, Edward
    Hou, Jinlin
    Buti, Maria
    JHEP REPORTS, 2023, 5 (10)
  • [49] Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients
    Fai-Meng Sou
    Tsung-Hui Hu
    Chao-Hung Hung
    Hsueh-Chou Lai
    Jing-Houng Wang
    Sheng-Nan Lu
    Cheng-Yuan Peng
    Chien-Hung Chen
    Hepatology International, 2020, 14 : 513 - 520
  • [50] Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients
    Sou, Fai-Meng
    Hu, Tsung-Hui
    Hung, Chao-Hung
    Lai, Hsueh-Chou
    Wang, Jing-Houng
    Lu, Sheng-Nan
    Peng, Cheng-Yuan
    Chen, Chien-Hung
    HEPATOLOGY INTERNATIONAL, 2020, 14 (04) : 513 - 520